3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Biliary Tract Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Turcot syndrome
1
Solid Tumor, Adult
1
Rectal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Efficacy
1
Digestive System Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Injections
7
pembrolizumab
5
Paclitaxel
5
Bevacizumab
5
Leucovorin
4
Fluorouracil
4
Carboplatin
4
trifluridine tipiracil drug combination
3
Pemetrexed
3
Oxaliplatin
3
Irinotecan
3
Docetaxel
3
Capecitabine
3
toripalimab
2
tislelizumab
2
fludarabine
2
Nivolumab
2
Gemcitabine
2
Fulvestrant
2
Cisplatin
2
BMS-753493
2
130-nm albumin-bound paclitaxel
2
urelumab
1
ulixertinib
1
palbociclib
1
mogamulizumab
1
lenvatinib
1
fluzoparib
1
duvelisib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Advanced Solid Tumors
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06819735
2026-05-06
DOMISOL
Domain Therapeutics SA
Phase 1/2
Recruiting
125 enrolled